Stanford University
Center for Academic Medicine, Division of Endocrinology & Diabetes, MC 5660
453 Quarry Road
Palo Alto, CA 94304-5660
United States
Stanford University is one of twenty-two type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Darrell Wilson, MD, the TrialNet team at Stanford University is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
Our Team
Darrell Wilson, MD
Starting with his initial training as an electrical engineer, Dr. Darrell Wilson has applied technology to improve the care of children and adolescents with endocrine problems, particularly emphasizing technology in carbohydrate abnormalities.
A Professor of Pediatrics at Stanford University, he is an internationally known clinical researcher concentrating in the area of pediatric diabetes and has published over 300 peer reviewed articles and chapters. He has been the Principal Investigator at Stanford University for TrialNet since its inception. He is a co-investigator on the NIH funded, multi-center Diabetes Research in Children Network (DirecNet). Over the past decade, this group has been devoted to testing how new technology such as glucose sensors can help children with diabetes, and has been extraordinarily productive. Further, he is a co-investigator on a number of Juvenile Diabetes Research Foundation funded clinical investigations devoted to the development of artificial pancreas.
Dr Wilson is a key member of Stanford University’s clinical research infrastructure, serving as the Chair of one of Stanford’s IRB panels as well as a member on the NIH funded CTRU advisory committee. At Stanford, he helps coordinates the clinical care for about 800 children and adolescents with diabetes. As an educator, he teachs medical students, residents, fellows, and clinical researchers across the Stanford campus and serve as an Associate Program Director for the Stanford University Pediatric Endocrine Fellowship training program.
Priya Prahalad, MD
Trudy Esrey, RD, CDE
Bonita Baker
Karen Barahona
Regional Affiliates
Affiliates provide opportunities for people who do not live near Stanford University. The affiliate sites listed below work with Stanford University to offer convenient participation in our research programs
Research Studies
If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More
Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More
TrialNet is testing a low dose of the immunotherapy drug anti-thymocyte globulin (ATG) to see if it can delay or prevent type 1 diabetes (T1D) in people ages 6 to 34 who have a 50% risk of clinical diagnosis (Stage 3) within 2 years. Risk is defined by having two or more autoantibodies and abnormal blood sugar (Stage 2), plus at least one high-risk marker (based on test results). In an earlier TrialNet study for people newly diagnosed with T1D, low-dose ATG preserved insulin production and improved blood sugar control for 2 years. Details
TrialNet researchers are testing two different treatments – abrocitinib and ritlecitinib – to see if either or both can preserve insulin production in people (ages 12-35) newly diagnosed with type 1 diabetes (Stage 3 T1D). Abrocitinib and ritlecitinib are in a new class of autoimmune treatments called Janus kinase (JAK) inhibitors. Details
TrialNet is testing rituximab-pvvr and abatacept in people (ages 8-45) who were newly diagnosed with type 1 diabetes (T1D) to learn if using both treatments, one after the other, maintains the body’s ability to make insulin. By adding abatacept after rituximab-pvvr, researchers predict more people will experience prolonged beta cell function during and possibly after treatment. Details
If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More
TrialNet is testing the safety of a new treatment, NNC0361-0041, in adults diagnosed with type 1 diabetes (T1D) in the past 48 months. This is a Phase 1 study, which means it is the first time this treatment is being tested for safety in people. If this study results in no safety concerns, we plan to conduct a larger study to see if this same treatment can slow down or stop T1D in people at high risk, before clinical diagnosis. More
